[1]
Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249, 505-510.
[2]
Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818-822.
[3]
Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov., 2010, 9, 537-550.
[4]
Dollins, C.M.; Nair, S.; Sullenger, B.A. Aptamers in immunotherapy. Hum. Gene Ther., 2008, 9, 443-450.
[5]
Wu, C.C.; Sabet, M.; Hayashi, T.; Tawatao, R.; Fierer, J.; Carson, D.A.; Guiney, D.G.; Corr, M. In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. Cell. Immunol., 2008, 251, 78-85.
[6]
Ruckman, J.; Green, L.S.; Beeson, J.; Waugh, S.; Gillette, W.L.; Henninger, D.D.; Claesson-Welsh, L.; Janjić, N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem., 1998, 273, 20556-20567.
[7]
Burmeister, P.E.; Lewis, S.D.; Silva, R.F.; Preiss, J.R.; Horwitz, L.R.; Pendergrast, P.S.; McCauley, T.G.; Kurz, J.C.; Epstein, D.M.; Wilson, C.; Keefe, A.D. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol., 2005, 12, 25-33.
[8]
Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105, 17356-17361.
[9]
Bagalkot, V.; Farokhzad, O.C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl., 2006, 45, 8149-8152.
[10]
Huang, Y.F.; Shangguan, D.; Liu, H.; Phillips, J.A.; Zhang, X.; Chen, Y.; Tan, W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem, 2009, 10, 862-868.
[11]
Diao, Y.; Liu, J.; Ma, Y.; Su, M.; Zhang, H.; Hao, X. A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo. Cancer Biol. Ther., 2016, 17, 498-506.
[12]
Yamada, Y.; Furukawa, R.; Harashima, H. A Dual-Ligand liposomal system composed of a cell-penetrating peptide and a mitochondrial rna aptamer synergistically facilitates cellular uptake and mitochondrial targeting. J. Pharm. Sci., 2016, 105, 1705-1713.
[13]
Zhang, J.; Chen, R.; Chen, F.; Chen, M.; Wang, Y. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles: A dual-functional strategy for paclitaxel delivery. J. Control. Release, 2015, 213, e137-e138.
[14]
Liu, J.; Wei, T.; Zhao, J.; Huang, Y.; Deng, H.; Kumar, A.; Wang, C.; Liang, Z.; Ma, X.; Liang, X.J. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Biomaterials, 2016, 91, 44-56.
[15]
Ng, E.W.; Shima, D.T.; Calias, P.; Cunningham, E.T. Jr.; Guyer, D.R.; Adamis, A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 2006, 5, 123-132.
[16]
Li, W.; Wang, K.; Zhao, M.; Yang, X.; Chen, M.; Lan, X. Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: Current status. Thromb. Res., 2014, 134, 769-773.
[17]
Li, W.; Lan, X. Aptamer Oligonucleotides: Novel potential therapeutic agents in autoimmune disease. Nucleic Acid Ther., 2015, 25, 173-179.
[18]
Steinbicker, A.U. AUID- Oho. A novel treatment of anemia of inflammation. Blood, 2014, 124, 2618-2619.
[19]
Nemeth, E. Anti-hepcidin therapy for iron-restricted anemias. Blood, 2013, 122, 2929-2931.
[20]
Kong, H.Y.; Byun, J. Nucleic Acid aptamers: New methods for selection, stabilization, and application in biomedical science. Biomol. Ther. (Seoul), 2013, 21, 423-434.
[21]
Schwoebel, F.; van Eijk, L.T.; Zboralski, D.; Sell, S.; Buchner, K.; Maasch, C.; Purschke, W.G.; Humphrey, M.; Zöllner, S.; Eulberg, D.; Morich, F.; Pickkers, P.; Klussmann, S. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood, 2013, 121, 2311-2315.
[22]
Boyce, M.; Warrington, S.; Cortezi, B.; Zöllner, S.; Vauléon, S.; Swinkels, D.W.; Summo, L.; Schwoebel, F.; Riecke, K. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br. J. Pharmacol., 2016, 173, 1580-1588.
[23]
van Eijk, L.T.; John, A.S.; Schwoebel, F.; Summo, L.; Vauléon, S.; Zöllner, S.; Laarakkers, C.M.; Kox, M.; van der Hoeven, J.G.; Swinkels, D.W.; Riecke, K.; Pickkers, P. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood, 2014, 124, 2643-2646.
[24]
Georgiev, P. The anti-hepcidin Spiegelmer Lexaptepid Pegol
(NOX-H94) as treatment of anemia of chronic disease in patients
with multiple myeloma, low grade lymphoma, and CLL: A phase II
pilot study. Ann. Meeting Am. Associat. Cancer Res, 2014.
[25]
Pencho Georgiev, M.L.; Luminita Ocroteala, J.G.; Emanuil Gheorghita, M.V. The anti-hepcidin spiegelmer® lexaptepid pegol (noxh94)
as treatment of anemia of chronic disease in patients with
multiple myeloma, low grade lymphoma, and cll: A phase ii pilot
study. the 19th Congress of the European Hematology Association
(EHA) in Milan, Italy, 12-15.
[26]
Waters, E.K.; Genga, R.M.; Schwartz, M.C.; Nelson, J.A.; Schaub, R.G.; Olson, K.A.; Kurz, J.C.; McGinness, K.E. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood, 2011, 117, 5514-5522.
[27]
Pipe, S. Visions in haemophilia care. Thromb. Res., 2009, 124(Suppl. 2), S2-S5.
[28]
Parunov, L.A.; Fadeeva, O.A.; Balandina, A.N.; Soshitova, N.P.; Kopylov, K.G.; Kumskova, M.A.; Gilbert, J.C.; Schaub, R.G.; McGinness, K.E.; Ataullakhanov, F.I.; Panteleev, M.A. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: Changing clot size by targeting extrinsic pathway initiation. J. Thromb. Haemost., 2011, 9, 1825-1834.
[29]
Gorczyca, M.E.; Nair, S.C.; Jilma, B.; Priya, S.; Male, C.; Reitter, S.; Knoebl, P.; Gilbert, J.C.; Schaub, R.G.; Dockal, M.; McGinness, K.E.; Pabinger, I.; Srivastava, A. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J. Thromb. Haemost., 2012, 10, 1581-1590.
[30]
Chang, J.Y.; Chantrathammachart, P.; Monroe, D.M.; Key, N.S. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb. Res., 2012, 130, e151-e157.
[31]
Gissel, M.; Orfeo, T.; Foley, J.H.; Butenas, S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb. Res., 2012, 130, 948-955.
[32]
Waters, E.K.; Genga, R.M.; Thomson, H.A.; Kurz, J.C.; Schaub, R.G.; Scheiflinger, F.; McGinness, K.E. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J. Thromb. Haemost., 2013, 11, 1137-1145.
[33]
Parunov, L.A.; Soshitova, N.P.; Fadeeva, O.A.; Balandina, A.N.; Kopylov, K.G.; Kumskova, M.A.; Gilbert, J.C.; Schaub, R.G.; McGinness, K.E.; Ataullakhanov, F.I.; Panteleev, M.A. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: Studies of spatial dynamics of fibrin clot formation in hemophilia A. Thromb. Res., 2014, 133, 112-119.
[34]
Blombery, P.; Scully, M. Management of thrombotic thrombocytopenic purpura: Current perspectives. J. Blood Med., 2014, 5, 15-23.
[35]
Sadler, J.E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood, 2008, 112, 11-18.
[36]
Huang, R.H.; Fremont, D.H.; Diener, J.L.; Schaub, R.G.; Sadler, J.E. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure, 2009, 17, 1476-1484.
[37]
Diener, J.L.; Daniel, L.H.A.; Duerschmied, D.; Merhi, Y.; Tanguay, J.F.; Hutabarat, R.; Gilbert, J.; Wagner, D.D.; Schaub, R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J. Thromb. Haemost., 2009, 7, 1155-1162.
[38]
Knobl, P.; Jilma, B.; Gilbert, J.C.; Hutabarat, R.M.; Wagner, P.G.; Jilma-Stohlawetz, P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfus. (Paris), 2009, 49, 2181-2185.
[39]
Mayr, F.B.; Knöbl, P.; Jilma, B.; Siller-Matula, J.M.; Wagner, P.G.; Schaub, R.G.; Gilbert, J.C.; Jilma-Stohlawetz, P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion, 2010, 50, 1079-1087.
[40]
Jilma-Stohlawetz, P.; Gorczyca, M.E.; Jilma, B.; Siller-Matula, J.; Gilbert, J.C.; Knöbl, P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb. Haemost., 2011, 105, 545-552.
[41]
Jilma-Stohlawetz, P.; Gilbert, J.C.; Gorczyca, M.E.; Knobl, P.; Jilma, B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb. Haemost., 2011, 106, 539-547.
[42]
Cataland, S.R.; Peyvandi, F.; Mannucci, P.M.; Lämmle, B.; Kremer Hovinga, J.A.; Machin, S.J.; Scully, M.; Rock, G.; Gilbert, J.C.; Yang, S.; Wu, H.; Jilma, B.; Knoebl, P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am. J. Hematol., 2012, 87, 430-432.
[43]
Bae, O.N. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch. Pharm. Res., 2012, 35, 1693-1699.
[44]
Sadler, J.E.; Budde, U.; Eikenboom, J.C.; Favaloro, E.J.; Hill, F.G.; Holmberg, L.; Ingerslev, J.; Lee, C.A.; Lillicrap, D.; Mannucci, P.M.; Mazurier, C.; Meyer, D.; Nichols, W.L.; Nishino, M.; Peake, I.R.; Rodeghiero, F.; Schneppenheim, R.; Ruggeri, Z.M.; Srivastava, A.; Montgomery, R.R.; Federici, A.B. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J. Thromb. Haemost., 2006, 4, 2103-2114.
[45]
Jilma, B.; Paulinska, P.; Jilma-Stohlawetz, P.; Gilbert, J.C.; Hutabarat, R.; Knobl, P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb. Haemost., 2010, 104, 563-570.
[46]
Jilma-Stohlawetz, P.; Knobl, P.; Gilbert, J.C.; Jilma, B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb. Haemost., 2012, 108, 284-290.
[47]
Firbas, C.; Siller-Matula, J.M.; Jilma, B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev. Cardiovasc. Ther., 2010, 8, 1689-1701.
[48]
Siller-Matula, J.M.; Merhi, Y.; Tanguay, J.F.; Duerschmied, D.; Wagner, D.D.; McGinness, K.E.; Pendergrast, P.S.; Chung, J.K.; Tian, X.; Schaub, R.G.; Jilma, B. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 902-909.
[49]
Xu, W.; Wang, T.Y.; Becker, R.C. Hematologic diseases: From within the heart. Rev. Esp. Cardiol., 2011, 64, 606-613.
[50]
Fitzhugh, C.D.; Lauder, N.; Jonassaint, J.C.; Telen, M.J.; Zhao, X.; Wright, E.C.; Gilliam, F.R.; De Castro, L.M. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am. J. Hematol., 2010, 85, 36-40.
[51]
Matsui, N.M.; Borsig, L.; Rosen, S.D.; Yaghmai, M.; Varki, A.; Embury, S.H. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood, 2001, 98, 1955-1962.
[52]
Jenison, R.D.; Jennings, S.D.; Walker, D.W.; Bargatze, R.F.; Parma, D. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev., 1998, 8, 265-279.
[53]
Gutsaeva, D.R.; Parkerson, J.B.; Yerigenahally, S.D.; Kurz, J.C.; Schaub, R.G.; Ikuta, T.; Head, C.A. Inhibition of cell adhesion by anti-P-selectin aptamer: A new potential therapeutic agent for sickle cell disease. Blood, 2011, 117, 727-735.
[54]
Mi, J.; Zhang, X.; Giangrande, P.H.; McNamara, J.O. 2nd; Nimjee, S.M.; Sarraf-Yazdi, S.; Sullenger, B.A.; Clary, B.M. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem. Biophys. Res. Commun., 2005, 338, 956-963.
[55]
Zennadi, R.; Hines, P.C.; De Castro, L.M.; Cartron, J.P.; Parise, L.V.; Telen, M.J. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood, 2004, 104, 3774-3781.
[56]
Burnette, A.D.; Nimjee, S.M.; Batchvarova, M.; Zennadi, R.; Telen, M.J.; Nishimura, J.; Sullenger, B.A. RNA aptamer therapy for vaso-occlusion in sickle cell disease. Nucleic Acid Ther., 2011, 21, 275-283.
[57]
Faryammanesh, R.; Lange, T.; Magbanua, E.; Haas, S.; Meyer, C.; Wicklein, D.; Schumacher, U.; Hahn, U. SDA, a DNA aptamer inhibiting E- and P-selectin mediated adhesion of cancer and leukemia cells, the first and pivotal step in transendothelial migration during metastasis formation. PLoS One, 2014, 9e93173
61
3